Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced that it has submitted a Phase I Clinical Trial Application (CTA) to the European Union for SR122, a dual‑targeting siRNA drug simultaneously inhibiting ApoC3 and PCSK9, marking a step in the company’s international expansion of its cardiometabolic RNAi pipeline aimed at dyslipidemia, including severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.
Regulatory Milestone
| Item | Detail |
|---|---|
| Filing Type | Phase I Clinical Trial Application (CTA) |
| Region | European Union |
| Product | SR122 (dual‑targeting siRNA) |
| Targets | ApoC3 + PCSK9 |
| Intended Indications | Dyslipidemia, including severe hypertriglyceridemia (sHTG) and mixed dyslipidemia |
| Announcement Date | 10 Nov 2026 |
Drug Profile & Mechanism of Action
- Molecule: SR122, a GalNAc‑conjugated siRNA designed for hepatocyte‑targeted delivery and potentially infrequent subcutaneous dosing characteristic of the GalNAc‑siRNA modality.
- Dual Targets: Simultaneously silences ApoC3 — a key regulator of triglyceride‑rich lipoprotein metabolism — and PCSK9, the validated driver of LDL‑C clearance; the two targets play complementary roles in lipid metabolism.
- Innovation: By addressing both triglyceride‑rich lipoproteins and LDL‑C through inhibition of complementary mechanisms, SR122 offers a differentiated therapeutic approach versus single‑target lipid‑lowering agents.
- Potential Clinical Benefit: Superior synergy in severe hypertriglyceridemia, with durable improvements across multiple lipid parameters and cardiometabolic risk factors — representing a potential step change in patient risk management. (Phase I trial design and endpoints: not disclosed.)
Market Impact & Outlook
- RNAi Cardiometabolic Race: Dual‑target lipid siRNA positions Ribo Life Science within a fast‑emerging class in which long‑acting genetic medicines aim to replace daily oral regimens and periodic injectables for high‑risk lipid patients.
- sHTG Unmet Need: Severe hypertriglyceridemia carries elevated pancreatitis and cardiovascular risk, and mixed dyslipidemia — with concurrent triglyceride and LDL‑C elevation — is only partially addressed by current single‑axis therapies, leaving room for a one‑drug, two‑pathway approach.
- EU Filing Strategy: Submitting a Phase I CTA to the European Union signals international development ambitions beyond China, leveraging the EU clinical trial regulation framework for multicenter early‑stage studies.
- Platform Validation: The filing extends the track record of Ribo Life Science’s GalNAc‑siRNA platform, underscoring the company’s ability to advance multi‑target RNAi constructs into clinical development.
- Watchpoints: Phase I safety and pharmacodynamic readouts, dosing interval data, and subsequent competitive positioning versus in‑class single‑target and dual‑target programs will shape SR122’s long‑term outlook.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development of SR122, EU regulatory review of the Phase I CTA, and potential therapeutic benefit in dyslipidemia, sHTG, and mixed dyslipidemia. Actual results may differ due to risks including CTA acceptance and trial initiation timelines, early‑phase safety outcomes, competitive product development, and commercialization execution.-Fineline Info & Tech
